Summary
Johnson & Johnson (JNJ) announced on July 11, 2006, the acquisition of Colbar LifeScience Ltd., a privately held Israeli biotechnology company, by its division Ortho-McNeil Pharmaceutical, Inc. This strategic move into reconstructive medicine and tissue engineering is significant as Colbar brings two key products, Evolence™ (collagen for facial wrinkles) and Ossix™ (dental membrane for bone regeneration), which are already marketed in various international regions and the US. The acquisition represents an investment in a specialized area of medical technology and expands JNJ's product portfolio. While the terms of the transaction were not fully disclosed, the company anticipates a one-time after-tax charge of approximately $50 million, or $0.02 per share, primarily for expensing in-process research and development. This charge is a common accounting treatment for such acquisitions and should be viewed as an investment in future growth rather than an ongoing operational expense.
Key Highlights
- 1Johnson & Johnson, through Ortho-McNeil Pharmaceutical, has acquired Colbar LifeScience Ltd., a biotechnology company.
- 2The acquisition focuses on reconstructive medicine and tissue engineering, indicating a strategic expansion into this medical field.
- 3Colbar LifeScience possesses two key products: Evolence™ (facial wrinkle treatment) and Ossix™ (dental membrane for bone regeneration).
- 4Evolence™ is already marketed in Europe, Canada, and Japan, while Ossix™ is available in the US and Europe.
- 5JNJ expects a one-time after-tax charge of approximately $50 million, or $0.02 per share, for in-process R&D related to the acquisition.
- 6The acquisition signals JNJ's commitment to innovation and growth in specialized medical sectors.